WO2013192565A3 - Use of ferric citrate in the treatment of chronic kidney disease patients - Google Patents

Use of ferric citrate in the treatment of chronic kidney disease patients Download PDF

Info

Publication number
WO2013192565A3
WO2013192565A3 PCT/US2013/047134 US2013047134W WO2013192565A3 WO 2013192565 A3 WO2013192565 A3 WO 2013192565A3 US 2013047134 W US2013047134 W US 2013047134W WO 2013192565 A3 WO2013192565 A3 WO 2013192565A3
Authority
WO
WIPO (PCT)
Prior art keywords
increase
iron
reduce
kidney disease
chronic kidney
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2013/047134
Other languages
French (fr)
Other versions
WO2013192565A2 (en
Inventor
Enrique Poradosu
Ron BENTSUR
James F. OLIVIERO III
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Keryx Biopharmaceuticals Inc
Original Assignee
Keryx Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP13807102.2A priority Critical patent/EP2863906B1/en
Priority to EP23219273.2A priority patent/EP4335436A3/en
Priority to HK15110673.6A priority patent/HK1210013B/en
Priority to CA2876982A priority patent/CA2876982A1/en
Priority to BR112014032049A priority patent/BR112014032049A2/en
Priority to JP2015518623A priority patent/JP2015535209A/en
Priority to MX2014015615A priority patent/MX2014015615A/en
Priority to KR1020207024260A priority patent/KR20200103855A/en
Priority to EA201590062A priority patent/EA201590062A1/en
Priority to EP20163104.1A priority patent/EP3730136B1/en
Priority to SG11201408521WA priority patent/SG11201408521WA/en
Priority to AU2013278000A priority patent/AU2013278000A1/en
Priority to KR1020157001458A priority patent/KR102150135B1/en
Priority to ES13807102T priority patent/ES2796254T3/en
Priority to HK16102352.0A priority patent/HK1214503A1/en
Priority to CN201380044271.0A priority patent/CN104884055A/en
Application filed by Keryx Biopharmaceuticals Inc filed Critical Keryx Biopharmaceuticals Inc
Publication of WO2013192565A2 publication Critical patent/WO2013192565A2/en
Priority to IL236356A priority patent/IL236356A0/en
Anticipated expiration legal-status Critical
Publication of WO2013192565A3 publication Critical patent/WO2013192565A3/en
Priority to AU2018203205A priority patent/AU2018203205B2/en
Priority to FR25C1043C priority patent/FR25C1043I1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Methods of administering ferric citrate to reduce and/or control serum phosphorus levels, increase serum bicarbonate levels, improve one or more iron storage parameters (e.g., increase serum ferritin levels, increase transferrin saturation (TSAT), increase hemoglobin concentration) increase iron absorption, maintain iron stores, treat iron deficiency, treat anemia, reduce the need for IV iron and/or reduce the need for erythropoiesis-stimulating agents (ESAs) in chronic kidney disease patients, are disclosed.
PCT/US2013/047134 2012-06-21 2013-06-21 Use of ferric citrate in the treatment of chronic kidney disease patients Ceased WO2013192565A2 (en)

Priority Applications (19)

Application Number Priority Date Filing Date Title
SG11201408521WA SG11201408521WA (en) 2012-06-21 2013-06-21 Use of ferric citrate in the treatment of chronic kidney disease patients
HK15110673.6A HK1210013B (en) 2012-06-21 2013-06-21 Use of ferric citrate in the treatment of chronic kidney disease patients
CA2876982A CA2876982A1 (en) 2012-06-21 2013-06-21 Use of ferric citrate in the treatment of chronic kidney disease patients
BR112014032049A BR112014032049A2 (en) 2012-06-21 2013-06-21 ferric citrate and oral iron supplement
JP2015518623A JP2015535209A (en) 2012-06-21 2013-06-21 Use of ferric citrate in the treatment of patients with chronic kidney disease
EP23219273.2A EP4335436A3 (en) 2012-06-21 2013-06-21 Use of ferric citrate in the treatment of chronic kidney disease patients
KR1020207024260A KR20200103855A (en) 2012-06-21 2013-06-21 Use of ferric citrate in the treatment of chronic kidney disease patients
EA201590062A EA201590062A1 (en) 2012-06-21 2013-06-21 APPLICATION OF LEMON-ACID IRON IN THE TREATMENT OF PATIENTS WITH CHRONIC RENOVAL INSUFFICIENCY
EP20163104.1A EP3730136B1 (en) 2012-06-21 2013-06-21 Use of ferric citrate in the treatment of chronic kidney disease patients
AU2013278000A AU2013278000A1 (en) 2012-06-21 2013-06-21 Use of ferric citrate in the treatment of chronic kidney disease patients
MX2014015615A MX2014015615A (en) 2012-06-21 2013-06-21 USE OF FERRIC CITRATE IN THE TREATMENT OF PATIENTS WITH CHRONIC RENAL DISEASE.
EP13807102.2A EP2863906B1 (en) 2012-06-21 2013-06-21 Use of ferric citrate in the treatment of chronic kidney disease patients
ES13807102T ES2796254T3 (en) 2012-06-21 2013-06-21 Use of ferric citrate in the treatment of patients with chronic kidney disease
HK16102352.0A HK1214503A1 (en) 2012-06-21 2013-06-21 Use of ferric citrate in the treatment of chronic kidney disease patients
CN201380044271.0A CN104884055A (en) 2012-06-21 2013-06-21 Application of ferric citrate in the treatment of patients with chronic kidney disease
KR1020157001458A KR102150135B1 (en) 2012-06-21 2013-06-21 Use of ferric citrate in the treatment of chronic kidney disease patients
IL236356A IL236356A0 (en) 2012-06-21 2014-12-18 Use of ferric citrate in the treatment of chronic kidney disease patients
AU2018203205A AU2018203205B2 (en) 2012-06-21 2018-05-08 Use of ferric citrate in the treatment of chronic kidney disease patients
FR25C1043C FR25C1043I1 (en) 2012-06-21 2025-11-18 USE OF FERRIC CITRATE IN THE TREATMENT OF PATIENTS WITH CHRONIC KIDNEY DISEASE

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201261662565P 2012-06-21 2012-06-21
US61/662,565 2012-06-21
US201361757229P 2013-01-28 2013-01-28
US61/757,229 2013-01-28
US201361800618P 2013-03-15 2013-03-15
US201361801050P 2013-03-15 2013-03-15
US61/801,050 2013-03-15
US61/800,618 2013-03-15

Publications (2)

Publication Number Publication Date
WO2013192565A2 WO2013192565A2 (en) 2013-12-27
WO2013192565A3 true WO2013192565A3 (en) 2015-10-15

Family

ID=49769729

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/047134 Ceased WO2013192565A2 (en) 2012-06-21 2013-06-21 Use of ferric citrate in the treatment of chronic kidney disease patients

Country Status (19)

Country Link
US (3) US20130345303A1 (en)
EP (3) EP3730136B1 (en)
JP (4) JP2015535209A (en)
KR (2) KR20200103855A (en)
CN (2) CN113244209A (en)
AU (2) AU2013278000A1 (en)
BR (1) BR112014032049A2 (en)
CA (1) CA2876982A1 (en)
DK (1) DK3730136T3 (en)
EA (1) EA201590062A1 (en)
ES (2) ES2796254T3 (en)
FR (1) FR25C1043I1 (en)
HK (1) HK1214503A1 (en)
IL (1) IL236356A0 (en)
MX (1) MX2014015615A (en)
NO (1) NO2025048I1 (en)
PL (1) PL3730136T3 (en)
SG (2) SG11201408521WA (en)
WO (1) WO2013192565A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108938585A (en) 2009-07-21 2018-12-07 凯克斯生物制药公司 Ferric citrate dosage form
TWI653043B (en) * 2012-12-20 2019-03-11 瑞士商伊蘭科動物健康公司 New use
SI3287133T1 (en) 2013-06-05 2019-09-30 Tricida Inc. Proton-binding polymers for oral administration
ES2856261T3 (en) * 2013-10-01 2021-09-27 Fresenius Medical Care Deutschland Gmbh Method and apparatus for determining a patient's daily iron loss
HK1223031A1 (en) * 2013-11-04 2017-07-21 凯克斯生物制药公司 Ferric citrate for reducing cardiac failure in chronic kidney disease patients
WO2015110968A1 (en) * 2014-01-23 2015-07-30 Lupin Limited Pharmaceutical grade ferric citrate and method for its production
EP3157516A4 (en) 2014-06-22 2017-12-13 Dexcel Pharma Technologies Ltd. Pharmaceutical compositions comprising ferric citrate and methods for the production thereof
LT3229816T (en) 2014-12-10 2020-05-25 Tricida Inc. PROTON CONNECTING POLYMERS FOR ORAL ADMINISTRATION
US20180071243A1 (en) * 2015-03-04 2018-03-15 Keryx Biopharmaceuticals, Inc. Use of ferric citrate in the treatment of iron-deficiency anemia
CN104688706B (en) * 2015-04-01 2017-07-14 成都欣捷高新技术开发有限公司 A kind of high drug load, ferrum citricum composition of Fast Stripping and preparation method thereof
WO2016162794A1 (en) * 2015-04-08 2016-10-13 Leiutis Pharmaceuticals Pvt Ltd Pharmaceutical compositions of ferric citrate
WO2016162888A1 (en) * 2015-04-09 2016-10-13 Actavis Group Ptc Ehf. Process for preparing pharmaceutical grade ferric citrate
WO2017193024A1 (en) 2016-05-06 2017-11-09 Tricida, Inc. Hcl-binding compositions for and method of treating acid-base disorders
US20210085711A1 (en) 2017-09-19 2021-03-25 Japan Tobacco Inc. Use of ferric citrate in prevention and/or treatment of iron-deficiency anemia in hypermenorrhea patient and/or patient suffering from hypermenorrhea-associated gynecologic disease
IL319146A (en) 2017-11-03 2025-04-01 Tricida Inc Compositions for and method of treating acid-base disorders
WO2019236639A1 (en) * 2018-06-04 2019-12-12 Tricida, Inc. Method of treating acid-base disorders
JP2022505697A (en) 2018-10-29 2022-01-14 ファーマコスモス ホールディング エー／エス Treatment of iron deficiency with ferric carboxymaltose
WO2022150623A1 (en) 2021-01-08 2022-07-14 Akebia Therapeutics, Inc. Compounds and composition for the treatment of anemia
CN117999069A (en) 2021-05-27 2024-05-07 凯克斯生物制药公司 Pediatric formulations of ferric citrate
CN115024495B (en) * 2022-06-27 2024-03-22 北京金康普食品科技有限公司 Nutritional composition for improving calcium and phosphorus metabolism of nephrosis patient and application thereof
WO2025181559A1 (en) * 2024-02-29 2025-09-04 Sloiron, Inc. Methods for determining the amount of encapsulated and free iron in a sample

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998026776A1 (en) * 1996-12-16 1998-06-25 Chen Hsing Hsu Method for treating renal failure
US20090186939A1 (en) * 2006-01-30 2009-07-23 Keith Chan Method of Treating Chronic Kidney Disease
WO2011011541A1 (en) * 2009-07-21 2011-01-27 Henry Trong Le Ferric citrate dosage forms

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0922461A4 (en) * 1996-07-19 2002-07-17 Nikken Chemicals Co Ltd REMEDIES FOR HYPERPHOSPHATEMIA
US8093423B2 (en) 2003-02-19 2012-01-10 Globoasia, Llc Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same
TWI335218B (en) 2003-02-19 2011-01-01 Panion & Bf Biotech Inc Ferric organic compounds, uses thereof and methods of making same
CN1600302A (en) * 2003-09-22 2005-03-30 宝龄富锦生技股份有限公司 Pharmaceutical composition containing ferric citrate, pharmaceutical grade ferric citrate and its preparation method, and dietary nutrition containing pharmaceutical grade ferric citrate
US20060134227A1 (en) * 2004-12-22 2006-06-22 Bortz Jonathan D Compositions including iron
NZ566743A (en) 2005-08-18 2010-07-30 Globoasia Llc Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same
EP1973549B1 (en) * 2006-01-06 2016-07-20 Luitpold Pharmaceuticals, Inc. Methods and compositions for administration of iron

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998026776A1 (en) * 1996-12-16 1998-06-25 Chen Hsing Hsu Method for treating renal failure
US20090186939A1 (en) * 2006-01-30 2009-07-23 Keith Chan Method of Treating Chronic Kidney Disease
WO2011011541A1 (en) * 2009-07-21 2011-01-27 Henry Trong Le Ferric citrate dosage forms

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
C. BOND ET AL.: "A Meta-Aanalysis Of Ferric Citrate For Hyperphosphatemia: The Effect odf an Oral Iron-Containing Phospahte Binder on Serum Ferritin and Saturated Transferrin in Hemodialysis Patients", NEPHROLOGY DIALYSIS TRANSPLANTATION, vol. 27, no. S2, May 2012 (2012-05-01), pages ii490, XP002740672 *
K. UMANATH ET AL.: "Rationale and study design of a three-period, 58-week trial of ferric citrate as a phosphate binder in patients with ESDR on dialysis", HEMODIALYSIS INTERNATIONAL, vol. 17, 15 June 2012 (2012-06-15), pages 67 - 74, XP002740674 *
M. SIKA ET AL.: "A Dose-Ranging And Efficacy Phase 3 Trial Of Ferric Citrate (FC) As A Phosphate Binder In Dialysis Patients", AM. J. KIDNEY DIS., vol. 57, no. 4, 2011, pages A89, XP002740671 *
T. CHRISTOPHER ET AL.: "Ferric Citrate: an Iron-Based Oral Phosphate Binder", RIDNEY RES. CLIN. PRACT., vol. 31, 20 June 2012 (2012-06-20), pages A38, XP002740673 *
WU-CHANG YANG: "An open-label, crossover study of a new phosphate-binding agent in haemodialysis patients: ferric citrate", NEPHROL. DIAL. TRANSPLANT., 1 January 2002 (2002-01-01), pages 265 - 270, XP055023585, Retrieved from the Internet <URL:http://ndt.oxfordjournals.org/content/17/2/265.full.pdf#page=1&view=FitH> [retrieved on 20120402] *
YOKOYAMA KEITARO ET AL: "Effect of oral JTT-751 (ferric citrate) on hyperphosphatemia in hemodialysis patients: results of a randomized, double-blind, placebo-controlled trial.", AMERICAN JOURNAL OF NEPHROLOGY 2012, vol. 36, no. 5, 2012, pages 478 - 487, XP008176600, ISSN: 1421-9670 *

Also Published As

Publication number Publication date
ES2796254T3 (en) 2020-11-26
EP3730136B1 (en) 2023-12-27
EP4335436A3 (en) 2024-05-15
US20140234416A1 (en) 2014-08-21
HK1214503A1 (en) 2016-07-29
JP2015535209A (en) 2015-12-10
EP2863906B1 (en) 2020-03-18
EP4335436A2 (en) 2024-03-13
IL236356A0 (en) 2015-02-26
CN113244209A (en) 2021-08-13
WO2013192565A2 (en) 2013-12-27
AU2018203205B2 (en) 2020-03-12
KR20200103855A (en) 2020-09-02
MX2014015615A (en) 2015-03-20
US20150079168A1 (en) 2015-03-19
JP2020100638A (en) 2020-07-02
HK1210013A1 (en) 2016-04-15
SG10201805177PA (en) 2018-07-30
BR112014032049A2 (en) 2017-07-25
JP2022070945A (en) 2022-05-13
AU2013278000A1 (en) 2015-01-22
CA2876982A1 (en) 2013-12-27
US20130345303A1 (en) 2013-12-26
PL3730136T3 (en) 2024-03-25
DK3730136T3 (en) 2024-01-22
KR102150135B1 (en) 2020-08-31
EP2863906A2 (en) 2015-04-29
NO2025048I1 (en) 2025-11-06
ES2970050T3 (en) 2024-05-24
AU2018203205A1 (en) 2018-05-31
EA201590062A1 (en) 2016-02-29
EP3730136A1 (en) 2020-10-28
JP2018138562A (en) 2018-09-06
CN104884055A (en) 2015-09-02
FR25C1043I1 (en) 2026-01-02
KR20150036131A (en) 2015-04-07
SG11201408521WA (en) 2015-01-29

Similar Documents

Publication Publication Date Title
WO2013192565A3 (en) Use of ferric citrate in the treatment of chronic kidney disease patients
HK1223031A1 (en) Ferric citrate for reducing cardiac failure in chronic kidney disease patients
JO2828B1 (en) Anti-Hepcidin Antibodies and Uses Thereof
WO2009125300A3 (en) Oxygenation procedures for newborns and devices for use therein
WO2013106646A3 (en) Compounds and methods for the inhibition of vcb e3 ubiquitin ligase
MY183637A (en) Compounds and uses thereof for the modulation of hemoglobin
EP4218816A3 (en) Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii
WO2013132498A3 (en) Inhalation of nitric oxide for treating respiratory diseases
SG158112A1 (en) Hepatocyte growth factor (hgf) binding proteins
WO2007143098A3 (en) Hepatocyte growth factor (hgf) binding proteins
IN2014MN02089A (en)
HK1204578A1 (en) Medicament for the treatment of acute myeloid leukemia (aml)
MY178654A (en) Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig protein scaffold for use in therapy
MY165499A (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
WO2013022740A3 (en) Gpr35 ligands and the uses thereof
WO2010102216A3 (en) Enhancing coagulation or reducing fibrinolysis
EA201591424A1 (en) METHODS OF TREATMENT OF IRON DEFICIENCY WITH SOLUBLE IRON PYROPHOSPHATE
WO2010119991A3 (en) Anti-hgf antibody combinational cancer therapies
HK1246649A1 (en) Use of ferric citrate in the treatment of iron-deficiency anemia
MX2015001508A (en) The use of antithrombin in extracorporeal membrane oxygenation.
WO2012075244A3 (en) Use of hemoglobin effectors to increase the bioavailability of therapeutic gases
BR112014009414A2 (en) use of whey protein micelles to improve insulin profile in diabetic patients
WO2013142153A3 (en) Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
HK1218883A1 (en) Treatment for exposure to nerve agent
JP2016511261A5 (en)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13807102

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2876982

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2014/015615

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2015518623

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 122019025430

Country of ref document: BR

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2013807102

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20157001458

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 201590062

Country of ref document: EA

Ref document number: A201500437

Country of ref document: UA

ENP Entry into the national phase

Ref document number: 2013278000

Country of ref document: AU

Date of ref document: 20130621

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112014032049

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112014032049

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20141219